Full Title
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants with Chronic Myeloid LeukemiaPurpose
Researchers want to find the best dose of TERN-701 to use in people with chronic myeloid leukemia (CML). The people in this study have CML that came back after treatment or could not be treated with standard therapies.
TERN-701 blocks a protein called BCR::ABL1, which causes cancer cells to multiply and grow. By blocking this protein, this drug may cause your cancer cells to die. TERN-701 blocks BCR::ABL1 differently than similar drugs for CML. This may make it more useful if other CML drugs have not worked for you. TERN-701 is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have CML that keeps growing after standard treatments, or you had side effects that made you unable to take those drugs.
- Have recovered from the serious side effects of previous treatments before taking TERN-701.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Michael Mauro’s office at 646-608-3744.
Protocol
24-225
Phase
Phase I (phase 1)
Disease Status
Relapsed or Refractory
Investigator
Co-Investigators
Diseases
ClinicalTrials.gov ID
NCT06163430